MAPK Signaling
Research Areas
Products Related to MAPK Signaling(660)
- GC44530p38 MAPK InhibitorCAS: 219138-24-6Purity: >98.00%
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM).
- GC44587PDMP (hydrochloride)CAS: 73257-80-4Purity: >98.00%
PDMP is a ceramide analog first prepared in a search for inhibitors of glucosylceramide synthase.
- GC44653PKA Inhibitor (5-24)CAS: 99534-03-9Purity: >98.50%
El inhibidor de PKA (5-24) es un inhibidor peptÍdico sintético, competitivo y potente de la PKA (proteÍna quinasa dependiente de AMPc), con una Ki de 2,3 nM.
- GC44852Rp-8-bromo-Cyclic AMPS (sodium salt)CAS: 925456-59-3Purity: >98%
Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.
- GC44853Rp-8-CPT-Cyclic AMP (sodium salt)CAS: 221905-35-7Purity: >98.00%
Rp-8-CPT-Cyclic AMP (sal de sodio), un anÁlogo de cAMP, es un antagonista potente y competitivo de la activaciÓn inducida por cAMP de PKA I y II dependiente de cAMP.
- GC44917Sorafenib N-oxideCAS: 583840-03-3Purity: >98.00%
Sorafenib N-oxide is an active metabolite of sorafenib, an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases.
- GC44920Sp-8-bromo-Cyclic AMPS (sodium salt)CAS: 1573115-90-8Purity: >98.00%
Sp-8-bromo-cyclic AMPS (Sp-8-bromo-cAMPS) is a cell-permeable, cAMP analog that combines an exocyclic sulfur substitution in the axial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP.
- GC45064Tomatidine (hydrochloride)CAS: 6192-62-7Purity: >98.00%
La tomatidina (clorhidrato) actúa como un agente antiinflamatorio al bloquear la señalización de NF-κB y JNK.
- GC45067Tpl2 Kinase InhibitorCAS: 871307-18-5Purity: >95.00%
Tpl2 Kinase Inhibitor (TKI) es un compuesto de naftiridina permeable a las células que actúa como un potente inhibidor reversible y competitivo de ATP de Tpl2 kinase
- GC46015KY 05009CAS: 1228280-29-2Purity: >99.50%
KY 05009 es un inhibidor de la cinasa que interactúa con Nck y Traf2 competitivo con ATP (TNIK) con una Ki de 100 nM. KY 05009 inhibe farmacológicamente la transición epitelial a mesenquimatosa (EMT) inducida por TGF-β1 en células de adenocarcinoma de pulmón humano. KY 05009 inhibe la expresión proteica de TNIK y la actividad transcripcional de los genes diana Wnt e induce la apoptosis en las células cancerosas. KY 05009 ejerce actividad anticancerígena.
- GC46123Comprehensive Kinase Screening LibraryPurity: >98.00%
For screening of a variety of kinase inhibitors
- GC465542'-O-Monosuccinyladenosine-3',5'-cyclic monophosphateCAS: 36940-87-1Purity: >98.00%
2'-O-Monosuccinyladenosine-3',5'-el monofosfato cÍclico es un anÁlogo de AMPc que puede acoplarse covalentemente a la acetilcolinesterasa.
- GC47045Carvedilol-d5CAS: 929106-58-1Purity: >99.00%
An internal standard for the quantification of carvedilol
- GC47088Cilostazol-d4CAS: 1215541-47-1Purity: >99.00%
An internal standard for the quantification of cilostazol
- GC47166Dabrafenib-d9CAS: 1423119-98-5Purity: >99.00%
Dabrafenib-d9 (GSK2118436A-d9) es el deuterio etiquetado como Dabrafenib. Dabrafenib (GSK2118436A) es un inhibidor de Raf competitivo con ATP con IC50 de 5 nM y 0,6 nM para C-Raf y B-RafV600E, respectivamente.
- GC47237Dipyridamole-d16CAS: 2712261-50-0Purity: >99.00%
A neuropeptide with diverse biological activities
- GC48329PKA Inhibitor (5-24) (trifluoroacetate salt)Purity: >95.00%
A synthetic peptide inhibitor of PKA
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC44530 | p38 MAPK Inhibitor | 219138-24-6 | >98.00% | |
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). | ||||
| GC44587 | PDMP (hydrochloride) | 73257-80-4 | >98.00% | |
PDMP is a ceramide analog first prepared in a search for inhibitors of glucosylceramide synthase. | ||||
| GC44653 | PKA Inhibitor (5-24) | 99534-03-9 | >98.50% | |
El inhibidor de PKA (5-24) es un inhibidor peptÍdico sintético, competitivo y potente de la PKA (proteÍna quinasa dependiente de AMPc), con una Ki de 2,3 nM. | ||||
| GC44673 | PQ-10 | 927691-21-2 | >98.00% | |
PQ-10 es un potente inhibidor de la fosfodiesterasa 10A (PDE10A) con IC50 y ED50 de 4,6 nM y 13 mg/kg, respectivamente. | ||||
| GC44852 | Rp-8-bromo-Cyclic AMPS (sodium salt) | 925456-59-3 | >98% | |
Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. | ||||
| GC44853 | Rp-8-CPT-Cyclic AMP (sodium salt) | 221905-35-7 | >98.00% | |
Rp-8-CPT-Cyclic AMP (sal de sodio), un anÁlogo de cAMP, es un antagonista potente y competitivo de la activaciÓn inducida por cAMP de PKA I y II dependiente de cAMP. | ||||
| GC44917 | Sorafenib N-oxide | 583840-03-3 | >98.00% | |
Sorafenib N-oxide is an active metabolite of sorafenib, an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. | ||||
| GC44920 | Sp-8-bromo-Cyclic AMPS (sodium salt) | 1573115-90-8 | >98.00% | |
Sp-8-bromo-cyclic AMPS (Sp-8-bromo-cAMPS) is a cell-permeable, cAMP analog that combines an exocyclic sulfur substitution in the axial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. | ||||
| GC45064 | Tomatidine (hydrochloride) | 6192-62-7 | >98.00% | |
La tomatidina (clorhidrato) actúa como un agente antiinflamatorio al bloquear la señalización de NF-κB y JNK. | ||||
| GC45067 | Tpl2 Kinase Inhibitor | 871307-18-5 | >95.00% | |
Tpl2 Kinase Inhibitor (TKI) es un compuesto de naftiridina permeable a las células que actúa como un potente inhibidor reversible y competitivo de ATP de Tpl2 kinase | ||||
| GC45099 | U-0126 | 109511-58-2 | >98.00% | |
Un inhibidor de MEK | ||||
| GC45902 | Trametinib-13C-d3 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC46015 | KY 05009 | 1228280-29-2 | >99.50% | |
KY 05009 es un inhibidor de la cinasa que interactúa con Nck y Traf2 competitivo con ATP (TNIK) con una Ki de 100 nM. KY 05009 inhibe farmacológicamente la transición epitelial a mesenquimatosa (EMT) inducida por TGF-β1 en células de adenocarcinoma de pulmón humano. KY 05009 inhibe la expresión proteica de TNIK y la actividad transcripcional de los genes diana Wnt e induce la apoptosis en las células cancerosas. KY 05009 ejerce actividad anticancerígena. | ||||
| GC46123 | Comprehensive Kinase Screening Library | - | >98.00% | |
For screening of a variety of kinase inhibitors | ||||
| GC46554 | 2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate | 36940-87-1 | >98.00% | |
2'-O-Monosuccinyladenosine-3',5'-el monofosfato cÍclico es un anÁlogo de AMPc que puede acoplarse covalentemente a la acetilcolinesterasa. | ||||
| GC46808 | ADTL-EI1712 | 2414916-45-1 | >98.00% | |
A dual ERK1 and ERK5 inhibitor | ||||
| GC47045 | Carvedilol-d5 | 929106-58-1 | >99.00% | |
An internal standard for the quantification of carvedilol | ||||
| GC47088 | Cilostazol-d4 | 1215541-47-1 | >99.00% | |
An internal standard for the quantification of cilostazol | ||||
| GC47166 | Dabrafenib-d9 | 1423119-98-5 | >99.00% | |
Dabrafenib-d9 (GSK2118436A-d9) es el deuterio etiquetado como Dabrafenib. Dabrafenib (GSK2118436A) es un inhibidor de Raf competitivo con ATP con IC50 de 5 nM y 0,6 nM para C-Raf y B-RafV600E, respectivamente. | ||||
| GC47237 | Dipyridamole-d16 | 2712261-50-0 | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC47771 | NG 25 (hydrochloride hydrate) | - | >98.00% | |
An inhibitor of MAP4K2 and TAK1 | ||||
| GC47931 | PDE4B Inhibitor | 2410550-31-9 | >98.00% | |
A PDE4B inhibitor | ||||
| GC48329 | PKA Inhibitor (5-24) (trifluoroacetate salt) | - | >95.00% | |
A synthetic peptide inhibitor of PKA | ||||
| GC48381 | 5'-pApA (sodium salt) | - | >95.00% | |
A linearized form of cyclic di-AMP | ||||
